Brief: Neurogene Launches Registrational Trial Design for NGN-401 Gene Therapy in Rett Syndrome Study
30/06/2025 21:11
June 30 (Reuters) - Neurogene Inc NGNE.O: NEUROGENE ANNOUNCES REGISTRATIONAL TRIAL DESIGN FOR EMBOLDEN™ STUDY OF NGN-401 GENE THERAPY FOR RETT SYNDROME NEUROGENE INC: REGISTRATIONAL TRIAL INITIATION ACTIVITIES UNDERWAY NEUROGENE INC: CASH RUNWAY EXTENDED INTO EARLY 2028 Source text: ID:nBw7LBY6Sa Further company coverage: NGNE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable